Apply to join our PCF Science Team! 👇

Breaking new👉 today @US_FDA approved capivasertib (oral AKT inhibitor) for the metastatic HSPC/APMS #prostatecancer with PTEN deficiency👉personalized medicine continues to leap forward👉Capitello-281 ph3 trial summary👇 @OncoAlert @urotoday @AUC3_Official

Excited to share results from the EQUIP study, just presented at @SNM_MI in Los Angeles. #SNMMI26 Last November, we installed the world's first @GEHealthCare Omni Total Body PET/CT - a 128cm long-axis field-of-view system with next-generation digital detectors. These are the first clinical results from anywhere in the world on this device. The short version: better images, in a fraction of the time. We enrolled 25 patients in a direct intra-individual comparison - same patient, same tracer injection, scanned first on a conventional PET/CT and then immediately on the Total Body system. Tracers included F-18 FDG, Ga-PSMA & DOTATATE, F-18 DCFPyL, and I-124. Striking results:: 83% reduction in acquisition time (2.5 min vs 15 min) - with superior image quality, and significantly better sharpness and lesion conspicuity. Remarkably, in 68% of patients, reviewers identified small lesions on Total Body PET that would have been missed on conventional imaging. Congratulations to Dr Alicia Corlett for an awesome oral presentation, Dr Cameron Pain, @pj_physics and all the co-investigators. Thanks to @Cancer_Research , @NIFAus, @unimelb and @PCF_Science for supporting this research. This was an investigator-initiated trial, funded by GE HealthCare. Link to abstract and images in comments..

Hearty congrats to @neerajaiims on his concurrent #ASCO26 presentation and @NEJM paper on his TALAPRO-3 data on combination of Talazoparib enzalutamide! @ASCO @PCF_Science nejm.org/doi/full/10.1056/NE…

@declangmurphy discusses the PROTEUS trial #ASCO26 - no real concerns about ADT as a comparator in the control arm. Notably complete responses are really uncommon in both arms. @ASCO @PCF_Science

#MaryEllenTaplin @DanaFarber_GU with first plenary of the day @asco #ASCO26 — phase 3 of #PROTEUS — >2100 patients w high risk #prostatecancer, adt and apalutamide improved path CR and also a highly powered statistically significant MFS benefit. @oncoalert @urotoday @PCF_Science

Mary-Ellen Taplin @DanaFarber delivers her PROTEUS presentation @ASCO #ASCO26 - with impressive effects on path CR and MFS! I’m looking forward to more forthcoming data as well! @PCF_Science

@ASCOPres Dr Eric Small delivers a powerful presidential talk — personal tribute to his partner Dr Amy Lin who passed this yr from a rare ovarian cancer. Oncology advancements needed — for every patient. Every cancer. Everywhere. @asco #ASCO26 @oncoalert @urotoday @oncbrothers

Eric Small’s @ASCOPres Address. Cancer is personal. It affects our families, friends, and neighbors. Translating science to clinics everywhere. #science @ucsfcc

@CaPsurvivorship @DanaFarber presents data on a crossover trial between enzalutamide and darolutamide for CNS adverse effects, showing clear differences between these drugs and based on chemistry that enables BBB penetration #ASCO26 @ASCO @PCF_Science

JUST In: TALAPRO-3 published in @NEJM Adding #talazoparib to enzalutamide/ADT =>3-year rPFS: 77% vs 56% in HRR-deficient metastatic prostate cancer ! Looking forward to full presentation by @neerajaiims who keeps changing SOC, one trial at a time. @ASCO #ASCO26 @OncoAlert

Breaking news #ASCO26 Adding Talazoparib to enzalutamide significantly ⬆️ rPFS 👉 HR 0.48 in pts w/ mCSPC (mAPMS) #prostatecancer w/ HRRm 👉 @NEJM paper tinyurl.com/vkvra8cd 👇 @ASCO @oncoalert @urotoday @PCF_Science @OpenMedicineHQ

LBA1/Plenary #ASCO26: PROTEUS trial Perioperative apalutamide ADT vs. placebo ADT with radical prostatectomy in HR localized or locally advanced PC Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage ! @DanaFarber @DanaFarber_GU @ASCO @OncoAlert

At #AACR26, @AndreaMiyahira caught up with PCF Investigator @VanAllenLab to congratulate him on winning the AACR-Wuan Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Watch to learn more.

Celebrating the next generation of researchers at the @AACR Annual Meeting! @AndreaMiyahira joined the 2026 recipients of the PCF Scholar-in-Training Awards, recognizing outstanding early-career scientists presenting impactful work in prostate cancer. #AACR26

PROX1 explored as a driver of neuroendocrine #ProstateCancer progression. @Bajji @DanaFarber joins @AndreaMiyahira @PCFnews in discussing #PROX1 as an epigenetically derepressed driver in neuroendocrine prostate cancer. #WatchNow on UroToday > bit.ly/47kzVEk

Targeting the regulator PTGES3 to suppress androgen receptor in resistant #ProstateCancer. Haolong Li, PhD @fredhutch joins @AndreaMiyahira @PCFnews to presents genome-scale CRISPRi screening using an endogenous AR reporter that identified PTGES3 as a top androgen receptor regulator. #WatchNow > bit.ly/3NGsFfo

Investigational all-in-one CAR T-cell platform for #ProstateCancer. @NourShobaki @PennMedicine joins @zklaassen_md @GACancerCenter to discuss an all-in-one CAR T platform targeting STEAP2, engineered to secrete PSMA CD28 bispecifics at tumor sites and resist TGF-β–mediated immunosuppression—promising preclinical leads now advancing toward IND-enabling studies. #WatchNow > bit.ly/3M3hlcm

Prof @MatthiasEiber from @TU_Muenchen is one of the PSMA PET/CT and Theranostics PIONEERS. Come and hear his insights from almost 15 years of PSMA experience at ProsTIC26: Case by Case Theranostics, September 3-5 in Melbourne, Australia. Find out more, and register before places run out: prostic26.org We have invited speakers from medical oncology, urology, radiation oncology, nuclear medicine, radiopharmaceutical sciences and industry. @pros_tic @PCF_Science

Clink link to article in European Urology. PSMA total tumour volume at 3months predicts overall survival independent of treatment in ENZAp. This raises important questions about how we should be measuring progression on PSMA. @ANZUPtrials @PCF_Science authors.elsevier.com/a/1mv80…

Safety and dosing of lutetium-PSMA in the pre-chemotherapy #PSMAfore trial. Oliver Sartor, MD @EJHospital sits down with @zklaassen_md @GACancerCenter reviewing PSMAfore safety data showing lutetium PSMA-617 is better tolerated in chemo‑naïve mCRPC than in the heavily pretreated VISION cohort, with fewer AEs and cytopenias. Standard dosing is 7.4 GBq q6w × 6, but he stresses tailoring to bone disease burden, confirming PSMA PET positivity, and checking counts/renal function—especially as many patients now prefer #Pluvicto over chemotherapy. #WatchNow > bit.ly/3OAiOYt @PCFnews @PCF_Science